Biocryst Pharmaceuticals Inc (BCRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX)

BCRX 7.030

+2.0%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	4/4/2007 12:09:29 PM
	of 269

Hadn't seen this or heard about the downgrade, but Leerink has been shorting the heck out of this sucker for over two months. Only the most sincere of intentions from Mr. Schwartz, of course........ BioCryst Dives on Fodosine IV Trial Halt Tuesday March 27, 4:40 pm ET BioCryst Pharmaceuticals Stock Drops As Company Stops IV Testing of Cancer Drug Fodosine NEW YORK (AP) -- BioCryst Pharmaceuticals Inc. shares hit a new 52-week low Tuesday after the company said it stopped part of a clinical trial for its cancer drug Fodosine. BioCryst said particles were found in a solution that was given to patients via IV in a leukemia study. Early tests indicate the stoppers on vials of Fodosine may be to blame, the company said, though the particles didn't affect the drug's potency. Leerink Swann & Co. analyst Joseph Schwartz downgraded the Birmingham, Ala.-based company's stock to "Market Perform" from "Outperform" and slashed his price target to $9 from $16. In addition to the delay in completing the intravenous arm of the study, he said newer tests show Fodosine is less effective than competing drugs. "While all other Fodosine trials will continue as planned, sine the formulation issue only applies to the IV form of the drug and not the oral capsules of Fodosine, we are concerned about the company's last-minute decision to switch Fodosine's lead indication to cutaneous T-cell lymphoma," he said. BioCryst shares fell $1.58, or 16.5 percent, to close at $8.00 on the Nasdaq Stock Market, having hit a new one-year low of $7.80 earlier in the session.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next